Pharmaceutical Commerce

Digital Edition

Read the May/June Issue now - It's Free!

 

 

The widely accepted statistic is that only about 10% of all adverse events (AEs) are reported to FDA. In 2010, that 10% equaled about 750,000 reports, which was an almost 31% increase over 2009 and the biggest year-over-year increase (as a percentage) in the last decade. The estimates for 2011 aren't due for another couple of months (per FDA), but they're expected to continue the upward trend. Pharmacovigilance experts agree that one of the main drivers of recent growth in AE reporting rates is, quite simply, increased awareness . . .
continued >

Rep overtime-pay issue will be argued at the Supreme Court next week

 

DDN sets up a dedicated service, Urgent Access, for continental US drug deliveries

 

US market for pharmaceuticals was $320 billion in 2011, says IMS Institute

 

Express Scripts' 2011 Drug Trend Report predicts negative trend growth in 2012

 

Cardinal Health settles with DEA; expands in China, and buys another regional US distributor Press reports of the acquisition of Dik Drug Co. remain uncorroborated by Cardinal continued >

Wait 'til next year on agg spend rules: CMS delays final regulations again Physician's Sunshine Act rules will not go into effect until 2013, with public reporting possible in 2014 continued >

'Big Data' analytics are coming to life sciences--but they're not there yet Genpact survey of finance offices at major life sciences companies finds that half believe their strategic financial performance is poor continued >

West Pharma adopts QbD practices for specifying syringe components Starting with the NovaPure brand, company will build out QbD design principles for its product lines continued >

Cold-chain services to global biopharma will be a $7.6-billion industry in 2013, rising to $8.9 billion in 2016 Latest forecast from Pharmaceutical Commerce sees 37% growth between 2010-2013; delays in biosimilars commercialization will hamper future growth continued >